Bover Sanjuan, JordiNavarro-Gonzalez, Juan FranciscoArenas, M DoloresTorregrosa, Jose-VicenteTamargo Menendez, Juande Francisco, Angel Luis MartinGonzalez-Parra, EmilioLloret Cora, M JesusSanchez Alvarez, J EmilioMartin-Malo, AlejandroMolina Vila, PabloBajo, M AuxiliadoraDaSilva Santos, Iara2023-01-252023-01-252018-07-07Bover Sanjuán J, Navarro-González JF, Arenas MD, Torregrosa JV, Tamargo Menéndez J, de Francisco ALM, et al. Pharmacological interactions of phosphate binders. Nefrologia (Engl Ed). 2018 Nov-Dec;38(6):573-578. English, Spanishhttp://hdl.handle.net/10668/13229The use of phosphate binders is one of basic elements in the treatment of CKD-MBD (“Chronic Kidney Disease-Mineral and Bone Disorder”). It has been well known for decades that phosphate reten tion through direct and indirect mechanisms, contributes to the generation and progression of secondary hyperparathy roidism (SHP) and renal osteodystrophy in chronic kidney disease (CKD).1,2 In fact, phosphate retention blocks all DOI of original article: https://doi.org/10.1016/j.nefro.2018.05.003. ∗ Corresponding author. E-mail address: jbover@fundacio-puigvert.es (J. Bover Sanjuán). hormonal counter-regulatory mechanisms, increases skeletal resistance to PTH and is considered a central factor in the and systemic alterations such as the decrease in calcitriol, increase in fibroblast growth factor-23 (FGF-23), cardiovascular calcifications, premature aging and the high morbi-mortality of these patients.2,3 For all this, phosphate has been considered as “the silent killer” of patients with CKDenAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/PhosphatesFibroblast growth factor-23Aging, prematureElectronic mailRenal insufficiency, chronicChelating agentsDrug interactionsHumansPhosphatesRenal insufficiency, chronicChronic kidney disease-mineral and bone disorderresearch article30473007open accessFosfatosInsuficiencia renal crónicaInteracciones farmacológicasQuelantesTrastorno mineral y óseo asociado a la enfermedad renal crónica10.1016/j.nefro.2018.05.0032013-2514https://doi.org/10.1016/j.nefro.2018.05.003